Skip to main content

Hedgehog Pathway

1
Pipeline Programs
2
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Exelixis
ExelixisCA - Alameda
1 program
1
BMS-833923Phase 1
Bristol Myers Squibb
1 program
BMS-833923PHASE_15 trials
Active Trials
NCT01357655Terminated70Est. Jan 2016
NCT00927875Completed5Est. Sep 2012
NCT00909402Completed39Est. Nov 2012
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bristol Myers SquibbBMS-833923
Bristol Myers SquibbBMS-833923
Bristol Myers SquibbBMS-833923
Bristol Myers SquibbBMS-833923
Bristol Myers SquibbBMS-833923

Clinical Trials (5)

Total enrollment: 194 patients across 5 trials

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Start: Sep 2011Est. completion: Jan 201670 patients
Phase 2Terminated

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

Start: Feb 2010Est. completion: Sep 20125 patients
Phase 1Completed

A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

Start: Nov 2009Est. completion: Nov 201239 patients
Phase 1Completed

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Start: Jul 2009Est. completion: Mar 201227 patients
Phase 1Completed

A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Start: Jul 2008Est. completion: May 201453 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.